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Background: The metabolic syndrome (MetS) is associated with cognitive deﬁcits and atherosclerotic
vascular disease. We examined whether the relation between the MetS and cognitive dysfunction is
mediated by measures of atherosclerosis or the presence of clinically manifest cardiovascular disease.
Methods: In 380 individuals (153 with MetS; 60–87 years) from the population based Hoorn Study, mea-
sures of atherosclerosis including carotid intima-media thickness (c-IMT), ﬂowmediated dilation (FMD),
ankle-brachial index and the presence of clinically manifest cardiovascular disease were assessed at
baseline and 7 later years at follow-up. Cognitive functioning (information processing speed, memory,
and attention and executive functioning) was assessed at follow-up. The relation between the MetS,
atherosclerosis and cognitive functioning was assessed with linear regression analysis.
Results: Individuals with MetS showed worse performance on information processing speed
(adjusted mean difference z-score± SE: −0.22±0.6; p=0.01) and attention and executive functioning
(−0.32±0.07; p<0.001), but not on the domainmemory. The affected cognitive domains were also asso-
ciated with measures of atherosclerosis (standardised B (95%CI) c-IMT: −0.14 (−0.24; −0.05); p<0.01;
FMD: 0.13 (0.02; 0.24), p<0.05) and a history of clinicallymanifest cardiovascular disease: (−0.29 (−0.47;
−0.11); p<0.01). However, the relation between theMetS and cognitive functioning did not change after
adjustment for c-IMT, FMD or a history of clinically manifest cardiovascular disease (p>0.05).
Conclusion: In this population based cohort, the relation between theMetS and cognitive dysfunctionwas
not mediated by atherosclerosis or a history of cardiovascular disease. These ﬁndings should stimulate
future studies to elucidate alternativemechanismsunderlying cognitive deﬁcits in individualswithMetS.. Introduction
The clustering of cardiovascular risk factors, often referred to as
hemetabolic syndrome (MetS), is associatedwith cognitive decre-
ents and the development of dementia [1,2]. This relationmay be
ediated by atherosclerotic vascular disease.
Individuals with MetS are at increased risk for carotidtherosclerosis, endothelial dysfunction, ischemic heart disease
nd cerebrovascular disease [3–5]. Atherosclerotic vascular dis-
ase may in turn affect the brain, not only by increasing the risk of
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thromboembolic stroke [6], but possibly also by affecting cerebral
perfusion, leading to malfunction and degeneration of neuronal
cells [7].
Large population-based studies have demonstrated a link
between indices of atherosclerosis and cognitive dysfunction or
dementia [8]. Affected cognitive domains include memory, infor-
mation processing speed, and executive functioning [9,10], a
cognitive proﬁlewhich is similar to the one observed in individuals
with the MetS [11]. Also in individuals without clinically manifest
cardiovascular disease, carotid intima media thickness predicted
subsequent cognitive decline [12].
Although atherosclerosis has often been considered to mediate
Open access under the Elsevier OA license.the relationbetween theMetS and cognitivedecline, thismediating
effect hasnot yet been studied in sufﬁcient detail. Thepresent study
therefore examined the relation between the MetS, atheroscle-
rosis and cognitive functioning in a population of non-demented
8 osclero
o
a
y
2
2
m
p
s
c
t
(
a
i
d
o
m
p
(
e
i
t
u
g
a
r
u
b
t
b
w
r
c
i
2
o
f
c
p
f
S
t
a
≥
2
2
l
d
s
e
g
t
b
i40 Y.D. Reijmer et al. / Ather
lder individuals. Presence of the MetS and several measures of
therosclerosis were related to a detailed cognitive assessment 7
ears later.
. Methods
.1. Study population
The Hoorn study is a population-based study on glucose
etabolism and cardiovascular risk in the general population. The
opulation and study design have been described earlier [13]. The
tudy started in 1989 and included 2484 randomly selected Cau-
asian participants aged 50–75 years from the middle-sized Dutch
own of Hoorn (T1). In 1996–1998 (T2), all surviving participants
n=2086) were invited for a second examination, to which 1513
greed [14]. In the 2000–2001 follow-up examination (T3), 1074
ndividuals of theHoorn study cohort, including all thosewhowere
iagnosed as having type 2 diabetes (n=176), and random samples
f individuals with normal (n=705) and impaired (n=193) glucose
etabolism, were invited, of whom 647 (60%) agreed to partici-
ate [15]. In 2005–2008 (T4) all independently living participants
n=549) were reinvited, to which 385 (70%) agreed to participate.
Cognitive functioning was only assessed at the 2005–2008
xamination. None of the participants had cognitive disturbances
nterfering with functional independence at the moment of cogni-
ive testing. For the present studywe excluded participantswith an
nreliable assessment of cognitive functioning (e.g. deafness, lan-
uage difﬁculties; n=5), leaving 380 participants for the present
nalyses. In the present paper, the 2000–2001 examination will be
eferred to as baseline, and the 2005–2008 examination as follow-
p.
Because we were interested in the possible causal relationship
etween the MetS, atherosclerosis and late life cognitive dysfunc-
ion, we deﬁned the MetS and measures of atherosclerosis at
aseline, 7 years prior to cognitive testing. In secondary analyses
e evaluated themediating effect of the progression of atheroscle-
osis over 7 years on the relation between the MetS at baseline and
ognitive functioning at follow-up.
The local ethics committee approved the study and written
nformed consent was obtained from all participants.
.2. The metabolic syndrome
The metabolic syndrome was deﬁned as having three or more
f the following criteria at baseline: waist circumference >88 cm
or women and >102 cm for men; triglycerides ≥1.7mmol/l; HDL
holesterol <1.3mmol/l forwomen and <1.0mmol/l formen; blood
ressure ≥130/85mm Hg (or antihypertensive medication), and
asting blood glucose ≥6.1mmol/l (ATP-III) (NCEP JAMA 2001).
ince information on 2-h postload glucose was also recorded in
his population, the glucose criterionwas slightlymodiﬁed andwas
lso considered fulﬁlled when the 2-h glucose concentration was
7.8mmol/l [16].
.3. Measures of atherosclerosis
.3.1. Carotid intima-media thickness (c-IMT)
Ultrasound assessment of the c-IMT was performed at base-
ine and follow-up. Procedures and reproducibility of scanning are
escribed in detail elsewhere [15]. In summary, an ultrasound
canner (350 Series; Pie Medical, Maastricht, The Netherlands),
quipped with a 7.5-MHz linear probe, was operated by a sin-
le observer. Three measurements, 4 s each, were performed in
he right common carotid artery at 10mm proximal to the carotid
ulb. The mean of these three measurements was calculated and
ncluded in the analysis. Images were registered and analysed by asis 219 (2011) 839–845
computer equippedwith vesselwallmovement detection software
and an acquisition system (Wall Track System; Pie Medical).
2.3.2. Endothelial function
Endothelium-dependent ﬂow-mediated dilation (FMD) of the
right brachial artery was assessed at baseline. The measurement
protocol has been described in detail [3]. Brieﬂy, baseline diame-
ter (mean of three measurements) and peak ﬂow velocity (mean
of two measurements) were determined. A pressure cuff, placed
on the forearm, was then automatically inﬂated and kept constant
at supra-systolic pressure (brachial systolic pressure +100mmHg)
in order to induce forearm ischemia. After 5min the cuff was
released, which is followed by an increase in blood ﬂow. This
increase in blood ﬂow increases shear stress, which serves as the
stimulus for FMD. After cuff release, the diameter was measured
at 45, 90, 180 and 300 s. The maximum diameter in any of these
four measurements was used in the statistical analysis. In addi-
tion, non-endothelium dependent nitroglycerin-mediated dilation
(NMD) was determined, which served as a control condition for
FMD. NMD was calculated as the percentage change in arterial
diameter from baseline to 5min after administration of 400g
sublingual nitroglycerin [3].
2.3.3. Clinically manifest cardiovascular disease
Peripheral vascular disease, ischemic heart disease and history
of stroke were assessed at baseline and follow-up. Peripheral vas-
cular disease was deﬁned as intermittent claudication assessed
with the Rose questionnaire, Ankle Brachial Index ≤0.9, history
of surgery or endovascular treatment for arterial disease, or lower
limb amputation. Ischemic heart disease was deﬁned asMinnesota
Code 1.1–1.3, 4.1–4.3, 5.1–5.3, or 7.1 on the electrocardiogram or
self-reported history of myocardial infarction. A history of stroke
was based on self-report. Any cardiovascular disease was deﬁned
as peripheral vascular disease, ischemic heart disease or history of
stroke.
2.4. Cognitive assessment
An extensive standardised neuropsychological test battery was
obtainedat the follow-upexamination, including twelve verbal and
non-verbal tasks, administered in a ﬁxed order. The tasks were
divided into six cognitive domains. This divisionwasmade a priori,
according to standard neuropsychological practice and cognitive
theory as described in detail by Lezak et al. [17]. For the present
study we focused on those cognitive domains which have previ-
ously been shown to be particularly affected in individuals with
theMetS and individualswith atherosclerosis, namely the domains
memory, information processing speed and attention and exec-
utive functioning [9,11]. The domain memory included tests for
four subdomains: ‘working memory’ assessed by the forward and
backward digit span of the Wechsler Adult Intelligence Scale-III
(WAIS-III) and the Corsi Block-Tapping Task; ‘immediate memory
and learning rate’, including verbal memory assessed by the Rey
Auditory Verbal Learning Test and visual memory assessed by the
Location Learning Test; ‘forgetting rate’ assessed by the delayed
recall of the Rey Auditory Verbal Learning Test and of the Location
Learning Test; and ‘incidental memory’ assessed by the delayed
trial of the modiﬁed Rey Complex Figure. The domain information
processing speed was assessed by the Trail Making Test Part A, the
Stroop Color-Word Test (Parts I and II), and the subtest Digit Sym-
bol of theWAIS-III. The domain attention and executive functionwas
assessedby theTrailMakingTest Part B, theStroopColor-WordTest
(Part III), the Brixton Spatial Anticipation Test, a letter ﬂuency test
using the ‘N’ and ‘A’, and category ﬂuency using animal names.
osclerosis 219 (2011) 839–845 841
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Table 1
Characteristics of the study population at baseline.
No MetS (n=227) MetS (n=153) p-Value
Age, years 67.8 ± 5.5 67.7 ± 5.4 n.s.
Sex (% male) 52% 48% n.s.
Estimated IQa 98 ± 12 97 ± 14 n.s.
Systolic blood pressure
(mmHg)
134 ± 18 147 ± 18 <0.001
Diastolic blood
pressure (mmHg)
79 ± 11 87 ± 10 <0.001
Antihypertensive
medication
22% 49% <0.001
BMI (kg/m2) 25.7 ± 2.7 29.6 ± 3.7 <0.001
Waist–hip ratio 0.90 ± 0.09 0.96 ± 0.09 <0.001
Total cholesterol
(mmol/l)
5.7 ± 1.0 5.7 ± 1.1 n.s.
HDL-cholesterol
(mmol/l)
1.5 ± 0.4 1.2 ± 0.4 <0.001
LDL-cholesterol
(mmol/l)
3.6 ± 0.9 3.6 ± 0.9 n.s.
Triglycerides (mmol/l) 1.2 ± 0.4 2.0 ± 1.0 <0.001
Cholesterol lowering
drugs
14% 22% 0.045
Fasting glucose
(mmol/l)
5.7 ± 0.9 6.6 ± 1.4 <0.001
2-h post-load glucose
(mmol/l)
6.3 ± 2.1 8.3 ± 2.7 <0.001
HbA1c (%) 5.8 ± 0.5 6.2 ± 0.8 <0.001
Diabetes 7% 31% <0.001
Current smoking 13% 9% n.s.Y.D. Reijmer et al. / Ather
Raw test scores were standardised into z-scores. One z-score
as derived for each domain by averaging tests comprising that
omain.
Pre-morbid IQ was estimated with the Dutch version of the
ational Adult Reading Test. Depressive symptoms were assessed
ith thevalidatedDutchversionof the20-itemCentre for Epidemi-
logic Studies Depression Scale (CES-D). The proportion of persons
coring ≥16 (indicating possible depression) was recorded.
.5. Other measurements
Systolic and diastolic blood pressure, body mass index (BMI),
aist-to-hip ratio, fasting glucose concentration, 2-h postload glu-
ose concentration, HbA1c levels, triglycerides, total cholesterol,
igh-density lipoprotein (HDL) cholesterol, low-density lipopro-
ein (LDL) cholesterol, were determined as described elsewhere
13]. The presence of diabetes was determined based on WHO cri-
eria (WHO 1999). Self-reported information on the participants’
urrent use of medications, medical history and current smoking
tatus (yes/no) was obtained by a standardised questionnaire.
.6. Statistical analysis
Demographic variables, vascular and metabolic risk factors lev-
ls, and measures of atherosclerosis were compared between
articipants with and without MetS with independent T-test for
ontinuous variables and chi-square test for proportions.
To answer the question whether the relation between the MetS
nd cognitive dysfunction is mediated by measures of atheroscle-
osis we ﬁrst assessed the associations between the MetS and
ognition, between the MetS and atherosclerosis, and between
therosclerosis and cognition with linear regression analyses,
djusted for age and sex, and cognition also for estimated IQ. The
ognitive domains onwhich theMetS group performedworse than
he noMetS group and the measures of atherosclerosis that were
igniﬁcantly related to cognitive performance were considered in
he mediation analyses.
The possible mediating effect of atherosclerosis on the rela-
ion between the MetS and cognitive performance was assessed
n a stepwise linear regression analysis in which we adjusted
he difference in cognitive performance between the noMetS and
etS group formeasures of atherosclerosis at baseline. The change
n between-group difference before and after adjustment for the
ediator (atherosclerosis) was assessed. In addition, we estimated
he corresponding 95% conﬁdence interval (CI) with a bootstrap-
ing technique [18]. Bootstrapping is a computer-based method
hat involves repeated sampling from the data and estimation of
he mediating effect in each resampled data set. By repeating this
rocess thousands of times, an empirical approximation of the
ampling distribution is built and used to reconstruct the 95% CI.
he mediating effect is said to be present if the 95% CI does not
ontain zero. We computed bootstrapped (bias-corrected) conﬁ-
ence intervals (5000 samples) for the size of the speciﬁcmediating
effects’ using SPPS macros provided by Preacher & Hayes [18].
In secondary models, alternative mediators of the relation
etween MetS and cognition were addressed. To prevent multi-
ollinearity thiswas done in six separatemodels for each individual
isk factor of theMetS (hypertension, hyperglycemia, dyslipidemia,
entral obesity), current smoking, andpossible depression. Because
he study population was enriched for type 2 diabetes, which is a
isk factor for cognitive decrements and atherosclerosis, we also
eanalysed the data after excluding all participants with type 2
iabetes.
Finally,weevaluatedwhether theprogressionof atherosclerotic
easures between baseline and follow-up mediates the relation
etween the MetS and cognition by repeating step 1 and 2 forData are presented as mean± SD or n (%).
a Assessed at follow-up.
measures of atherosclerosis assessed at follow-up, adjusted for the
baseline measurement.
3. Results
Table 1 shows the baseline characteristics of the participants
with and without MetS. Groups did not differ in age, sex or esti-
mated IQ. Of the 153 participants with the MetS, 120 (78%) scored
above the cut-off for waist circumference, 93 (61%) for triglyceride
levels, 73 (48%) for HDL levels, 143 (94%) for blood pressure levels,
and 120 (78%) for glucose levels. The raw cognitive test scores of
both groups are presented in Table 2.
3.1. The MetS and atherosclerosis at baseline and cognitive
functioning at follow-up
Individualswith theMetShadagreater c-IMT,worseendothelial
function, reﬂected by a lower FMD and similar NMD, and a higher
prevalence of ischemic heart disease at baseline than individu-
als without the MetS (Table 3). Regarding cognition, individuals
with the MetS showed worse performance at follow-up on the
domain information processing speed (adjusted mean z-score± SE
noMetS: 0.09±0.5, MetS: −0.13±0.06; p=0.01) and attention and
executive functioning (noMetS: 0.13±0.06, MetS: −0.19±0.07;
p<0.001). No signiﬁcant difference in memory performance was
observed (Table 4).
The relation between markers of atherosclerosis at baseline
and cognitive functioning at follow-up in the whole popula-
tion is shown in Table 5. An increased c-IMT was associated
with worse information processing speed (standardised B (95%CI):
−0.14(−0.24; −0.05); p=0.004) and attention and executive func-
tioning (−0.11 (−0.21; −0.01); p=0.04). Decreased FMD was
associated with worse attention and executive functioning (stan-
dardised B (95%CI): 0.13 (0.02; 0.24), p=0.02). The presence
of ischemic heart disease or any CVD was associated with
worse information processing speed (B (95% CI) ischemic heart
disease:−0.21(−0.40; −0.02), p=0.03; any CVD: −0.29 (−0.47;
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Table 2
Raw cognitive test scores.
Range of scores Controls (n=227) MetS (n=153)
Information processing speed
Trail making test part A (s)a 20–161 49.3 ± 19.9 51.5 ± 21.9
Stroop color word test I (s)a 32–133 47.9 ± 8.0 49.9 ± 11.6
Stroop color word test II (s)a 39–137 63.6 ± 11.8 66.1 ± 16.0
Symbol substitution test 18–94 52.4 ± 14.5 49.7 ± 14.4
Attention and executive functioning
Trail making test part B (s)a 41–407 121.3 ± 62.3 139.8 ± 69.9
Stroop color word test III (s)a 50–467 125.2 ± 46.4 137.9 ± 58.3
Brixton spatial anticipation test (errors)a 7–47 20.7 ± 7.4 21.9 ± 6.9
Letter ﬂuency (mean N+Á) 2–24 11.0 ± 4.2 10.1 ± 4.0
Category ﬂuency (No. of animals) 8–63 30.8 ± 8.4 30.3 ± 9.0
Memory
Working memory
WAIS-II digit span forward (productscore) 12–126 45.1 ± 17.9 44.8 ± 19.7
WAIS-II digit span backward (productscore) 4–104 25.0 ± 15.9 21.6 ± 13.2
Corsi Block-Tapping test forward (productscore) 9–96 38.5 ± 12.2 36.5 ± 12.7
Corsi Block-Tapping test backward (productscore) 2–88 34.7 ± 15.5 34.4 ± 15.9
Immediate memory and learning rate
RALVT total trials 1–5 (words) 5–61 36.2 ± 10.4 35.4 ± 9.9
LLT total trials 1–5 (errors)a 0–163 34.2 ± 26.2 29.8 ± 23.2
Forgetting rate
RAVLT delay (words) 0–15 6.8 ± 3.4 6.8 ± 3.0
LLT delay (errors)a 0–33 4.3 ± 5.9 3.3 ± 4.3
RAVLT recognition (words) 0–30 27.6 ± 3.0 27.8 ± 3.2
Incidental memory
Rey Complex Figure Test delay (points) 0–30 14.2 ± 6.3 14.2 ± 6.3
RAVLT: Rey auditory verbal learning test; LLT: location learning test. Raw test scores pe
except when indicated.
a Higher scores indicate poorer performance.
Table 3
Between-group differences in measures of atherosclerosis at baseline.
No MetS (n=227) MetS (n=153) p-Value
c-IMT, mm 0.83 ± 0.17 0.88 ± 0.15 0.01
Endothelial dependent
FMDa, %
4.7 ± 3.8 3.7 ± 3.1 0.02
Non-endothelial
dependent NMDb, %
10.7 ± 5.4 9.9 ± 5.8 0.21
ClinicallymanifestCVD
Peripheral vascular
diseasec
33 (15%) 25 (17%) 0.61
Ischemic heart diseased 77 (34%) 65 (43%) 0.09
History of stroke 19 (8%) 10 (7%) 0.50
Any CVDe 111 (49%) 79 (52%) 0.60
a Flow mediated (endothelial dependent) dilation of the brachial artery.
b Nitroglycerinmediated (endothelial independent)dilationof thebrachial artery.
c Rose questionnaire: intermittent claudication, ABI <0.9, arterial operation or
amputation.
d Self reported history of myocardial infarction or ischemic heart disease on ECG.
d
−
a
c
(
T
G
D
ee History of peripheral vascular disease, myocardial infarction, ischemic heart
isease on ECG, or stroke.
0.11), p=0.002). A trendwas observed between ahistory of stroke
t baseline andworse performance on the domain information pro-
essing speed (−0.56 (−1.15; 0.025); p=0.06) and memory (−0.63
−1.26; 0.01); p=0.05).
able 4
roup differences in cognitive performance at follow-up.
No MetS (n=227) MetS (n=153) p-Value
Info processing speed 0.09 ± 0.05 −0.13 ± 0.06 0.01
Attention and
executive
functioning
0.13 ± 0.06 −0.19 ± 0.07 <0.001
Memory −0.06 ± 0.06 0.09 ± 0.07 n.s.
ata are presented as mean standardised z-scores± SE adjusted for age, sex and
stimated IQ.r group are represented as mean± SD. Higher scores indicate better performance
3.2. Mediation of the association between the MetS and cognition
by baseline atherosclerosis
As can be seen from Table 6, the mean difference in informa-
tion processing speed between theMetS and noMetS group did not
notably change after additional adjustment for c-IMT, FMD and any
CVD at baseline (change in between-group difference ﬁnal model:
0.03). The corresponding 95%CI estimated with the bootstrap
method (−0.06; 0.05) indicated that these measures of atheroscle-
rosis did not signiﬁcantly mediate the association between MetS
and cognition, because the 95%CIs contain zero and are relatively
narrow. Also the mean group difference in attention and executive
functioning did not change after adjustment for atherosclerosis at
baseline (change in between-group difference ﬁnal model (boot-
strap 95%CI): 0.01 (−0.07; 0.01)). Further adjustment for current
smoking, and possible depression did not alter the results (data
not shown). Of the ﬁve individual risk factors of the MetS, only
hyperglycemia slightly mediated the relation between the MetS
and information processing speed (−0.10 (−0.22; −0.003)), but
not between MetS and attention and executive functioning (−0.06
(−0.16; 0.05)).
3.3. The association between the MetS, baseline atherosclerosis
and cognition in individuals without type 2 diabetes
After exclusion of all individuals with type 2 diabetes (n=64),
the noMetS group included 211 individuals and the MetS
group 105 (mean age 67.7±5.6 and 67.5±5.2, respectively).
The between-group differences in measures of atherosclerosis,
cognitive functioning and the relation between measures of
atherosclerosis at baseline and cognition at follow-up were sim-
ilar to the values from the analyses that included the patients with
type 2 diabetes, as shown in Tables 3–5 (supplementary material
online). Only thedifference in endothelial dependent FMDbetween
the MetS and noMets group became smaller and non-signiﬁcant
(noMetS: 4.8±3.8, MetS: 4.2±3.4). Similar to the results shown
in Table 6, the group difference in information processing speed
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Table 5
Relation between measures of atherosclerosis at baseline and cognition at follow-up in the whole study sample (n=380).
Information processing speed Attention and executive functioning Memory
c-IMT, mm −0.14 (−0.24; −0.05)** −0.11 (−0.21; −0.01)* −0.10 (−0.21; 0.002)
Endothelial dependent FMDa,f, % 0.05 (−0.05; 0.16) 0.13 (0.02; 0.24)* −0.02 (−0.13; 0.09)
Non-endothelial dependent NMDb,f, % 0.05 (−0.05; 0.16) 0.01 (−0.04; 0.18) 0.10 (−0.02; 0.21)
Clinically manifest CVD
Peripheral vascular diseasec −0.21 (−0.46; 0.05) 0.03 (−0.24; 0.30) −0.25 (−0.52; 0.02)
Ischemic heart diseased −0.21 (−0.40; −0.02)* 0.07 (−0.14; 0.27) −0.01 (−0.22; 0.19)
History of stroke −0.56 (−1.15; 0.03) −0.22 (−0.85; 0.41) −0.63 (−1.26; 0.01)
Any CVDe −0.32 (−0.49; −0.14)** 0.07 (−0.13; 0.26) −0.16 (−0.35; 0.04)
Regression coefﬁcients indicate the change in z-score per SD for continuous variables and per category (no/yes) for dichotomous variables, adjusted for age and sex.
a Flow mediated dilation of the brachial artery.
b Nitroglycerin mediated dilation of the brachial artery.
c Rose questionnaire: claudicatio, ABI <0.9, arterial operation or amputation.
d Self reported history of myocardial infarction or ischemic heart disease on ECG.
e History of peripheral vascular disease, myocardial infarction, ischemic heart disease on ECG, or stroke.
f Lower values reﬂect worse function.
* p<0.05.
** p<0.01.
Table 6
Mean difference in cognitive performance at follow-up between individualswith (n=153) andwithout (n=227) theMetS adjusted formeasures of atherosclerosis at baseline.
Information processing speed Attention and executive functioning
Age, sex, estimated IQ −0.22 (−0.38; −0.05)* −0.32 (−0.49; −0.14)***
Previous + c-IMT −0.19 (−0.36; −0.02)* −0.33 (−0.52; −0.15)***
Previous + endothelial dependent FMDa −0.24 (−0.43; −0.06)* −0.33 (−0.52; −0.15)***
Previous + any CVDb −0.25 (−0.43; −0.07)** −0.33 (−0.52; −0.14)***
a Flow mediated dilation of the brachial artery.
b History of peripheral vascular disease, myocardial infarction, ischemic heart disease on ECG, or stroke.
(
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o* p<0.05.
** p<0.01.
*** p<0.001.
−0.27±0.09; p=0.003) and attention and executive function-
ng (−0.32±0.10; p=0.002) did not change after adjustment for
easures of atherosclerosis at baseline (change in between-group
ifference (bootstrap 95%CI): 0.03 (−0.08; 0.02) and −0.03 (−0.06;
.02), respectively) (Table 7).
.4. Mediation of the association between the MetS and cognition
y the progression of atherosclerosis between baseline and
ollow-up
After correction for the baseline measurements of atheroscle-
osis, there was no association between c-IMT, peripheral vascular
isease or ischemic heart disease at follow-up and cognitive func-
ioning at follow-up (all p>0.05). However, incident stroke (stroke
etween baseline and follow-up) was associated with reduced
nformation processing speed (−0.56 (−0.97; −0.14); p=0.01), but
ot with attention and executive functioning or memory perfor-
ance. Incident stroke did not mediate the relation between the
etS and worse performance on information processing speed or
ttention and executive functioning (change in between-group dif-
erence (bootstrap 95%CI): −0.02 (−0.07; 0.01) and −0.005 (−0.03;
.004)) respectively.
able 7
ean difference in cognitive performance at follow-up between individuals with (n=105)
f atherosclerosis at baseline.
Information process
Age, sex, estimated IQ −0.27 (−0.45; −0.09
Previous + c-IMT −0.25 (−0.44; −0.07
Previous + endothelial dependent FMDa −0.31 (−0.51; −0.12
Previous + any CVDb −0.30 (−0.49; −0.11
a Flow mediated dilation of the brachial artery.
b History of peripheral vascular disease, myocardial infarction, ischemic heart disease o
** p<0.01.4. Discussion
In the present population-based study both theMetS andmark-
ers of atherosclerosis were associated with reduced cognitive
functioning, but the relationbetween theMetSandcognitivedecre-
ments was not mediated by measures of atherosclerosis or the
presence of clinically manifest cardiovascular disease.
The proﬁle and size of the cognitive decrements we observed
in individuals with MetS are in line with previous ﬁndings, reﬂect-
ing mild reductions in information processing speed and attention
and executive functioning [1,11]. Problemswithmemory have also
been reported [19]. However, in contrast to our study, previous
studies primary assessed immediate verbal memory performance,
whichstronglydependsonattentional capacity, andnot somuchon
the capability to consolidate information. Differences in cognitive
performanceweremainly observed on testswith a high attentional
demand (Table2), indicating that the cognitiveproblems in individ-
ualswithMetSwill becomemost evident in complex situations, e.g.
when two tasks are executed simultaneously. The use of a detailed
cognitive assessment allowed us to detect subtle decrements in
cognitive functioning before it became clinically manifest. Exam-
ining underlying mechanisms of these early stages of cognitive
andwithout (n=211) theMetS andwithout type 2 diabetes, adjusted formeasures
ing speed Attention and executive functioning
)** −0.32 (−0.52; −0.12)**
)** −0.32 (−0.52; −0.12)**
)** −0.29 (−0.48; −0.09)**
)** −0.29 (−0.49; −0.09)**
n ECG, or stroke.
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ysfunction is relevant, because treatment beneﬁts are expected
o be largest when the underlying brain damage is still relatively
odest.
Our results on the relation between cognitive performance and
easures of carotid atherosclerosis [10,20], endothelial function
20] and clinically manifest cardiovascular disease [9,21] are also
n agreement with results from previous population based stud-
es. The important ﬁnding of our study is that despite the fact
hat we conﬁrm that the MetS and atherosclerosis are both asso-
iated with impaired cognition, we now clearly demonstrate that
therosclerosis does not modulate the relation between the MetS
ndcognition. In addition to traditionalmediationanalyses,wealso
alculated the respective 95% CI of the mediation effect by using a
ootstrapping technique. This technique provides information on
he reliability of the point estimates for possible mediation effects.
he observed 95% CIs were relatively narrow, indicating that the
ediation effect could be reliably estimated in this study sample.
lthough the modulating role of atherosclerosis on the relation
etween MetS and cognition had not yet been studied in sufﬁcient
etail, it has often been proposed as an important mechanism. Our
esults however, do not support this hypothesis, indicating that
ther mechanisms are likely to play a role. For example, etiologi-
al factors shared between atherosclerosis and the MetS, such as
nﬂammation, may drive the association with cognition. Chronic
nﬂammation is an important risk factor for atherosclerosis and is
inked with the MetS and age-related cognitive decline [11,22]. In
ddition, each component of the MetS is individually associated
ith atherosclerosis and reduced cognitive functioning [23]. Previ-
us studies have identiﬁed hyperglycemia as the main contributor
o deﬁcits in cognitive functioning in individualswithMetS [11,24].
lso in our study hyperglycemia slightly modulated the relation
ith information processing speed.
The other components of theMetS, including hypertension, adi-
osity and hypercholesterolemia, did also not mediate the relation
etween the MetS and cognitive functioning in this study. How-
ver, this does not rule out the association between MetS and the
evelopment of cognitive dysfunction. Indeed, exposure to vascu-
ar risk factors at midlife has shown to be more strongly related to
ate life cognitive function than exposure to these risk factors dur-
ng late life [25,26]. The age at which the vascular risk factors are
ssessed should therefore be considered in interpretation of these
esults.
Our ﬁndings do not exclude that the relation betweenMetS and
ognitive dysfunction is mediated by other manifestations of vas-
ular disease, such as cerebral small vessel disease. Small vessel
isease, such as white matter abnormalities and (lacunar) infarcts,
s more common in individuals with MetS [24,28,29] and is associ-
ted with a similar cognitive proﬁle,including mental slowing and
roblemswithexecutive functioning [27].Unfortunately, brainMRI
ata was not available from our cohort.
To our knowledge, we are the ﬁrst to examine the impact of
therosclerosis on the association between the MetS and cogni-
ive dysfunction. Strengths of this study are the detailed recording
f measures of atherosclerosis over a long follow-up period in a
ell-deﬁned population-based cohort, as well as the comprehen-
ive assessment of cognitive functioning. However, somemeasures
f cardiovascular disease, such as stroke, were based on self-report.
nother limitation is attrition, which can lead to selection bias.
lthough this is inherent to the longitudinal design and the inten-
ive character of this study, thismayhave led to anunderestimation
f the effects because subjects with severe vascular disease or cog-
itive deﬁcits are more likely to drop out. Indeed, previous reports
n the Hoorn study population have shown that cardiovascular
ortality was associated with an unfavourable risk factor proﬁle
t baseline [30]. Our results apply therefore to the variation in
ognitive functioning in a relatively healthy population of oldersis 219 (2011) 839–845
individuals, but cannot be generalised to the risk of developing
dementia. Finally, cognition was only assessed once. Therefore we
were not able to determine which individuals showed cognitive
decline.
Despite these limitations, we still observe an association
between the MetS, atherosclerosis and cognition, supporting the
notion that also mild forms of atherosclerosis are related to worse
cognitive functioning.
5. Conclusion
These results indicate that atherosclerosis or the presence of
clinically manifest cardiovascular disease does not account for
the observed reductions in cognitive functioning in individuals
with the MetS. Whether shared vascular and metabolic risk fac-
tors of MetS and atherosclerosis play a role in the development of
cognitive deﬁcits remains to be elucidated. Understanding these
mechanisms is essential for future intervention studies aiming to
reduce the detrimental effect of MetS on the brain.
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